154 related articles for article (PubMed ID: 19486467)
1. Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study.
Hansen N; Obel N; Christensen PB; Krarup H; Laursen AL; Clausen MR; Lunding S; Møller A; Schlichting P; Kromann-Andersen H; Bukh J; Weis N;
J Viral Hepat; 2009 Sep; 16(9):659-65. PubMed ID: 19486467
[TBL] [Abstract][Full Text] [Related]
2. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
Sulkowski MS; Mehta SH; Torbenson MS; Higgins Y; Brinkley SC; de Oca RM; Moore RD; Afdhal NH; Thomas DL
AIDS; 2007 Oct; 21(16):2209-16. PubMed ID: 18090048
[TBL] [Abstract][Full Text] [Related]
3. Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area.
Mariano A; Caserta C; Pendino GM; Vacalebre C; Surace P; Fiorillo MT; Polito I; Surace M; Alicante S; Amante A; Foti G; Marra M; Gutamo G; Amato F; Messineo A; Mele A
Dig Liver Dis; 2009 Jul; 41(7):509-15. PubMed ID: 19196557
[TBL] [Abstract][Full Text] [Related]
4. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Aug; 79(8):1095-102. PubMed ID: 17597485
[TBL] [Abstract][Full Text] [Related]
5. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
[TBL] [Abstract][Full Text] [Related]
6. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
[TBL] [Abstract][Full Text] [Related]
7. The impact of HIV-1 co-infection on long-term mortality in patients with hepatitis C: a population-based cohort study.
Omland LH; Jepsen P; Skinhøj P; Jørgensen HL; Münster AM; Bangsborg J; Fenger M; Sørensen HT; Obel N
HIV Med; 2009 Feb; 10(2):65-71. PubMed ID: 19018878
[TBL] [Abstract][Full Text] [Related]
8. Liver function under interferon/ribavirin therapy of chronic hepatitis C.
Stintzing S; Schmitt C; Ocker M; Ganslmayer M; Zopf S; Gahr S; Hahn EG; Herold C
Hepatogastroenterology; 2009; 56(90):462-5. PubMed ID: 19579621
[TBL] [Abstract][Full Text] [Related]
9. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.
d'Arminio Monforte A; Cozzi-Lepri A; Castagna A; Antinori A; De Luca A; Mussini C; Caputo SL; Arlotti M; Magnani G; Pellizzer G; Maggiolo F; Puoti M;
Clin Infect Dis; 2009 Aug; 49(4):612-22. PubMed ID: 19591597
[TBL] [Abstract][Full Text] [Related]
10. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study.
Omland LH; Krarup H; Jepsen P; Georgsen J; Harritshøj LH; Riisom K; Jacobsen SE; Schouenborg P; Christensen PB; Sørensen HT; Obel N;
J Hepatol; 2010 Jul; 53(1):36-42. PubMed ID: 20400197
[TBL] [Abstract][Full Text] [Related]
11. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
[TBL] [Abstract][Full Text] [Related]
12. HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection.
Denholm JT; Wright EJ; Street A; Sasadeusz JJ
Haemophilia; 2009 Mar; 15(2):538-43. PubMed ID: 19187189
[TBL] [Abstract][Full Text] [Related]
13. When to treat and the benefits of treating hepatitis C in patients with haemophilia.
Patel H; Heathcote EJ
Haemophilia; 2009 Jan; 15(1):20-32. PubMed ID: 18976253
[TBL] [Abstract][Full Text] [Related]
14. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
[TBL] [Abstract][Full Text] [Related]
15. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.
La Mura V; De Renzo A; Perna F; D'Agostino D; Masarone M; Romano M; Bruno S; Torella R; Persico M
J Hepatol; 2008 Oct; 49(4):557-63. PubMed ID: 18678434
[TBL] [Abstract][Full Text] [Related]
16. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
[TBL] [Abstract][Full Text] [Related]
17. Detection of hepatitis C virus in platelets: evaluating its relationship to antiviral therapy outcome.
de Almeida AJ; Campos-de-Magalhães M; Brandão-Mello CE; de Oliveira RV; do Espirito-Santo MP; Yoshida CF; Lampe E
Hepatogastroenterology; 2009; 56(90):429-36. PubMed ID: 19579615
[TBL] [Abstract][Full Text] [Related]
18. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
[TBL] [Abstract][Full Text] [Related]
19. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.
Pineda JA; Aguilar-Guisado M; Rivero A; Girón-González JA; Ruiz-Morales J; Merino D; Ríos-Villegas MJ; Macías J; López-Cortés LF; Camacho A; Merchante N; Del Valle J;
Clin Infect Dis; 2009 Oct; 49(8):1274-82. PubMed ID: 19772387
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection.
Mas Marques A; Mueller T; Welke J; Taube S; Sarrazin C; Wiese M; Halangk J; Witt H; Ahlenstiel G; Spengler U; Goebel U; Schott E; Weich V; Schlosser B; Wasmuth HE; Lammert F; Berg T; Schreier E
Infect Genet Evol; 2009 Sep; 9(5):847-52. PubMed ID: 19446659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
